Andrew D. Abell, William Tieu, Angie M. Jarrad, Tatiana P. Soares da Costa, John C. Wallace, Ashleigh S. Paparella, Kelly A. Keeling, Steven W. Polyak, Grant W. Booker, Tieu, William, Jarrad, Angie M, Paparella, Ashleigh S, Keeling, Kelly A, Soares Da Costa, Tatiana P, Wallace, John C, Booker, Grant W, Polyak, Steven W, and Abell, Andrew D
Inhibitors of Staphylococcus aureus biotin protein ligase (SaBPL) are generated by replacing the acyl phosphate group of biotinyl-5′-AMP with either a 1,2,3-triazole (see 5/10a/10b) or a 1,2,4-oxadiazole (see 7) bioisostere. Importantly, the inhibitors are inactive against the human BPL. The nature of the 5-substituent in the component benzoxazolone of the optimum 1,2,3-triazole series is critical to activity, where this group binds in the ATP binding pocket of the enzyme. Refereed/Peer-reviewed